5-(3-(2-(2-((2-(1-(3-fluoro-4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl)quinolin-6-yl)oxy)ethoxy)ethyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (A)
. To a solution of 3c (30 mg) in 1 mL DMF under N 2 , 0.7 mL DIPEA were added followed by the addition of 40 mg FITC and the reaction stirred for 6 h at rt protected from light. After solvent evaporation, final compound was purified by preparative HPLC. (80 %). 1 Ethyl 4-((2-ethynylquinolin-6-yl)oxy)butanoate (9). 8 (250 mg, 0.7 mmol) was dissolved in anh DCM (7 mL). Next, 1.0 M TBAF in hexanes (0.84 mL) was added dropwise under N 2 and the reaction mixture was stirred at rt for 1 min. Upon completion 10 mL of 10% citric acid were added and the mixture stirred for 30 min. After washing with H 2 O, the organic phase was dried over anh Na 2 SO 4 , concentrated under vacuum and the product used in the next step without further purification. (92% 
Synthesis of NVS compounds
Final compounds NVS-1, and NVS-6 were obtained following the synthetic route previously reported (Scheme S3). 
General method for synthesis of 3,4-dihydro-2H-benzo[e][1,3]oxazin-2-one (11, 12).
Cyclohexylamine or 4-methoxyaniline (3.96 mmol, 1 eq) were added to a solution of 2-hydroxy-4-methoxybenzaldehyde (3.96 mmol) in 19 mL of absolute EtOH at rt. The mixture obtained was stirred for 1.5 h. After cooled to 0 °C, NaBH 4 (11.88 mmol, 3 eq) was added in portions. The mixture was stirred for 3 h at rt, poured into H 2 O (30 mL) and extracted with DCM (50 mL). The organic layer was dried over anh Na 2 SO 4. After filtration carbonyl-diimidazole (5.94 mmol, 1.5 eq) was added and the mixture stirred for 16 h at rt. Additional carbonyl-diimidazole (3.09 mmol, 0.78 eq) was added and the reaction stirred for 3 h at rt. Then, the mixture was washed with 1 N HCl solution (50 mL), a saturated NaHCO 3 solution (50 mL) and brine (50 mL), dried over anh Na 2 SO 4 and concentrated under vacuum. Desired intermediates were used in the next step without further purification. NVS-2 was synthesized following the synthetic route described in the Scheme S4. In order to avoid deprotection of both methoxy groups this compound has been obtained through intermediate 13. 
3-cyclohexyl-

7-methoxy-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[e][1,3]oxazin-2-one (12). (27%
7-hydroxy-3-(4-hydroxyphenyl)-3,4-dihydro-2H-benzo[e][1,3]oxazin-2-one, NVS-6. (21%
Synthesis of compounds 5. (E)-1-((1,2-dichlorovinyl)oxy)-4-methoxybenzene (15).
To a solution of 500 mg of 4-metthoxyphenol (4 mmol) in 4 mL DMSO, 160 mg of powder NaOH were added and stirred for 2h at rt. 1,1,2-trichloroethene (0.36 mL, 4 mmol) was added dropwise and the resulting solution stirred at rt for 2h. After completion of the reaction, the reaction was quenched with H 2 O and extracted with DCM (x2). The organic phases were combined and dried over Na 2 SO 4 . After solvent evaporation, the resulting product was used in the next step without further purification. 
2-fluoro-4-(4-(4-methoxyphenoxy)-1H-1,2,3-triazol-1-yl)phenol (5a
2-(4-(ethynyloxy)phenyl)-4,5-dihydrooxazole (19)
.
HPP and FP assays
Tautomerase assay. Inhibition of the tautomerase activity of MIF was measured using 4-hydroxyphenyl pyruvic acid (HPP) as substrate, largely following previously reported protocols. 
